Moderna and SpaceX highlighted by a fast-growing U.S. fund traded in London

Baillie Gifford U.S. Growth Trust devoted much of its half-yearly report to talking up the prospects of biotech Moderna and rocket launcher SpaceX, two of its investments that helped lift its net asset value surge during the time frame.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.